Omeros Corporation has announced the submission of a Marketing Authorization Application $(MAA)$ to the European Medicines Agency $(EMA)$ for narsoplimab, aiming to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This MAA submission includes analyses demonstrating a 61% response rate and a significant improvement in overall survival compared to a well-matched external control group. Narsoplimab has been granted orphan drug designation by the EMA, allowing for a centralized review process covering all EU member states and certain European Economic Area countries. The review process is set to commence in mid-July, with a final decision expected by mid-2026. This submission follows the acceptance of the resubmission of the Biologics License Application $(BLA.AU)$ for narsoplimab by the U.S. FDA, with a target action date set for September 25, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.